Physical Activity, Quality of Life, and Burden of Arrhythmia Following Successful Catheter Ablation for Atrial Fibrillation

Abstract

BACKGROUND: Vasovagal syncope (VVS) is a common clinical problem that significantly reduces quality of life yet lacks effective medical therapies. Midodrine is an alpha1-adrenergic receptor agonist pro-drug with a short half-life that requires a multiple dose regimen. Existing literature suggests that midodrine might provide effective suppression of recurrent VVS, but studies have used heterogeneous methods and have yielded inconsistent results. The objective of this systematic review was to evaluate the efficacy of midodrine to prevent syncope in patients with recurrent VVS.